Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 4:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Continuous Subcutaneous Insulin Infusion Clear all
Completed Phase 2 Interventional Results available

Artificial Pancreas Control System in an Inpatient Setting

NCT01552603
View directory record Official record
Conditions
Type I Diabetes Mellitus
Interventions
Artificial Pancreas Control Software
Device
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 4 Interventional Results available

Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus

NCT00607087
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin glulisine, Insulin lispro, Insulin aspart
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 30, 2010 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 4 Interventional Results available

A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)

NCT03662334
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Rapid Acting insulin with pre-treatment of rHuPH20, Sham injection
Drug · Device
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Not applicable Interventional Results available

Shared Medical Decision Making in Pediatric Diabetes

NCT02496156
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Usual Clinical Practice, Shared Medical Decision Making
Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
11 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 4 Interventional

NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes

NCT00095446
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Not applicable Interventional Results available

The Insulin-Only Bionic Pancreas Bridging Study- Pediatric Transitional Study

NCT04112069
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog, Usual Care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Palo Alto, California • Aurora, Colorado • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 4 Interventional Results available

Intravenous Insulin vs Subcutaneous Insulin Infusion in Intrapartum Management of Type 1 Diabetes Mellitus

NCT04599075
View directory record Official record
Conditions
Type 1 Diabetes, Pregnancy, High Risk
Interventions
Insulin
Drug
Lead sponsor
Gianna Wilkie
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2024 · Synced Sep 26, 2026, 4:35 AM EDT
Completed No phase listed Observational

Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) Therapy

NCT01104142
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CGM
Device
Lead sponsor
DexCom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 14, 2010 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Not applicable Interventional Results available

Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use

NCT02137512
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Closed-Loop Control System, Sensor-Augmented Pump (SAP)
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 69 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Santa Barbara, California • Stanford, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Not applicable Interventional

Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis

NCT02930044
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
Early administration of subcutaneous insulin glargine dose, IV insulin infusion, IV fluid repletion
Other · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 4 Interventional Results available

Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness

NCT00530023
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MiniMed Paradigm REAL-Time System
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
Loma Linda, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Not applicable Interventional Results available

Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)

NCT00357890
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
Insulin pump therapy, Multiple daily injections using insulin glargine + rapid acting analog
Device · Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 26, 2026, 4:35 AM EDT
Terminated Phase 1 Interventional Results available

A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes

NCT02588950
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
U-500R
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

Artificial Pancreas Control System in an Outpatient Setting

NCT01871870
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Artificial Pancreas Control Software
Device
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants

NCT01749137
View directory record Official record
Conditions
Overweight
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
6
States / cities
Miami, Florida • Lexington, Kentucky • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes

NCT03433677
View directory record Official record
Conditions
Diabetes Type 1
Interventions
LY900014, Insulin lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Fresno, California • Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Not applicable Interventional Results available

Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM

NCT02558491
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Decision Support System, Usual Care
Device · Other
Lead sponsor
Daniel Chernavvsky, MD
Other
Eligibility
21 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 1 Interventional

Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion

NCT02603510
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
SAR342434, insulin lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Little Rock, Arkansas • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Not applicable Interventional Results available

Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control

NCT00945659
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Continuous Glucose Sensor, Standard Care, CGS + Behavior Therapy
Device · Other · Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
11 Years to 16 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 4 Interventional Results available

U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod

NCT00606034
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Resistance
Interventions
U-500 Insulin delivered by Omnipod (disposable insulin pump)
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Not applicable Interventional Results available

Inpatient Closed-loop Glucose Control

NCT01819844
View directory record Official record
Conditions
Diabetes Mellitus, Hyperglycemia
Interventions
Closed-loop blood glucose control
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 1 Interventional Results available

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

NCT03095651
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg, Glargine 0.4 U/kg, Placebo to Glargine, Placebo to MK-5160, Dextrose, Glargine 0.6 U/kg
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2019 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Not applicable Interventional Results available

Closed Loop Insulin Pump Therapy After Islet Auto-Transplantation

NCT01945138
View directory record Official record
Conditions
Chronic Pancreatitis, Diabetes Mellitus
Interventions
Closed Loop Insulin
Device
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 64 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Not applicable Interventional

A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (T1D)

NCT03743285
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
AID System, Insulin Lispro
Device · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Sep 26, 2026, 4:35 AM EDT